New DiaP277 analogue shifts DCs to tolerogenic, and modulates NF-Kβ1 to suppress autoreactive T lymphocytes in the type 1 diabetic mice

References

• Roep BO, Tree T. Immune modulation in humans: implications for type 1 diabetes mellitus. Nat Rev Endocrinol. 2014;10:229–242.
   PubMed Web of Science ®Google Scholar
• Juwono J, Martinus RD. Does Hsp60 provide a link between mitochondrial stress and inflammation in diabetes mellitus? J Diabetes Res. 2016;2016:1.
   Google Scholar
• Yuan J, Dunn P, Martinus RD. Detection of Hsp60 in saliva and serum from type 2 diabetic and non-diabetic control subjects. Cell Stress Chaperones. 2011;16:689–693.
   PubMed Web of Science ®Google Scholar
• Hall L, Martinus RD. Hyperglycaemia and oxidative stress upregulate HSP60 & HSP70 expression in HeLa cells. Springerplus. 2013;2:431.
   PubMedGoogle Scholar
• Chee CS, Chang KM, Loke MF, et al. Association of potential salivary biomarkers with diabetic retinopathy and its severity in type-2 diabetes mellitus: a proteomic analysis by mass spectrometry. PeerJ. 2016;4:e2022.
   PubMed Web of Science ®Google Scholar
• Abulafia-Lapid R, Elias D, Raz I, et al. T cell proliferative responses of type 1 diabetes patients and healthy individuals to human hsp60 and its peptides. J Autoimmun. 1999;12:121–129.
   PubMed Web of Science ®Google Scholar
• Elias D, Reshef T, Birk OS, et al. Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein. Proc Natl Acad Sci U S A. 1991;88:3088–3091.
   PubMed Web of Science ®Google Scholar
• Bluestone JA, Buckner JH, Fitch M, et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med. 2015;7:315ra189–315ra189.
   PubMed Web of Science ®Google Scholar
• Elias D, Marcus H, Reshef T, et al. Induction of diabetes in standard mice by immunization with the p277 peptide of a 60-kDa heat shock protein. Eur J Immunol. 1995;25:2851–2857.
   PubMed Web of Science ®Google Scholar
• Coppieters KT, Sehested Hansen B, von Herrath MG. Clinical potential of antigen-specific therapies in type 1 diabetes. Rev Diabet Stud. 2012;9:328–337.
   PubMedGoogle Scholar
• Clemente-Casares X, Tsai S, Huang C, et al. Antigen-specific therapeutic approaches in type 1 diabetes. Cold Spring Harbor Perspect Med. 2012;2:a007773.
   PubMed Web of Science ®Google Scholar
• Raz I, Ziegler AG, Linn T, et al. Treatment of recent-onset type 1 diabetic patients with DiaPep277: results of a double-blind, placebo-controlled, randomized phase 3 trial. Dia Care. 2014;37:1392–1400.
   PubMed Web of Science ®Google Scholar
• Cohen IR, FJ Quintana G, Nussbaum M, et al. HSP60 and the regulation of inflammation: physiological and pathological. In: van Eden W, editor. Heat shock proteins and inflammation. Basel: Birkhäuser Basel, 2003. p. 1–13.
   Google Scholar
• Ma Y, Liu J, Hou J, et al. Oral administration of recombinant Lactococcus lactis expressing HSP65 and tandemly repeated P277 reduces the incidence of type I diabetes in non-obese diabetic mice. PLoS One. 2014;9:e105701.
   PubMed Web of Science ®Google Scholar
• Cohen IR. Peptide therapy for Type I diabetes: the immunological homunculus and the rationale for vaccination. Diabetologia. 2002;45:1468–1474.
   PubMed Web of Science ®Google Scholar
• Siegel-Itzkovich J. Scientists develop a “vaccine” against diabetes. BMJ. 2001;323:1272–1272.
   PubMedGoogle Scholar
• Liu Jingjing JIN. Immunological adjuvant with immunity vegulating agent for treating and preventing diabetic from insulin-dependent. China Pharmaceutical UNIV. 2006. PAT - CN1831012.
   Google Scholar
• Sarikonda G, Sachithanantham S, Miller JF, et al. The Hsp60 peptide p277 enhances anti-CD3 mediated diabetes remission in non-obese diabetic mice. J Autoimmun. 2015;59:61–66.
   PubMed Web of Science ®Google Scholar
• Eldor R, Kassem S, Raz I. Immune modulation in type 1 diabetes mellitus using DiaPep277: a short review and update of recent clinical trial results. Diabetes Metab Res Rev. 2009;25:316–320.
   PubMed Web of Science ®Google Scholar
• Dominguez Md C, Lorenzo N, Barbera A, et al. An altered peptide ligand corresponding to a novel epitope from heat-shock protein 60 induces regulatory T cells and suppresses pathogenic response in an animal model of adjuvant-induced arthritis. Autoimmunity. 2011;44:471–482.
   PubMed Web of Science ®Google Scholar
• Xiong Q, Jin L, Li J, et al. A Th2 immune shift to heat shock protein 65 fails to arrest atherosclerosis: proatherogenic role of Th2-deviated autoantibodies. Autoimmunity. 2009;42:475–483.
   PubMed Web of Science ®Google Scholar
• Schloot NC, Cohen IR. DiaPep277® and immune intervention for treatment of type 1 diabetes. Clin Immunol. 2013;149:307–316.
   PubMed Web of Science ®Google Scholar
• Pozzilli P, Raz I, Peled D, et al. 2015. Evaluation of long-term treatment effect in a type 1 diabetes intervention trial: differences after stimulation with glucagon or a mixed meal. Dia Care. 2014;37:1384–1391.
   PubMed Web of Science ®Google Scholar
• Fust G, Uray K, Bene L, et al. Comparison of epitope specificity of anti-heat shock protein 60/65 IgG type antibodies in the sera of healthy subjects, patients with coronary heart disease and inflammatory bowel disease. Cell Stress Chaperones. 2012;17:215–227.
   PubMed Web of Science ®Google Scholar
• Guo S, Wang R, Yang Z, et al. Effects of atorvastatin on serum lipids, serum inflammation and plaque morphology in patients with stable atherosclerotic plaques. Exp Ther Med. 2012;4:1069–1074.
   PubMed Web of Science ®Google Scholar
• Sambrook J, Russell DW. SDS-polyacrylamide gel electrophoresis of proteins. Cold Spring Harbor Protocols. 2006;2006:pdb.prot4540.
   Google Scholar
• Schmitz J, Zimmer JP, Kluxen B, et al. Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59. J Clin Invest. 1995;96:1520–1526.
   PubMed Web of Science ®Google Scholar
• Lutz MB, Kukutsch NA, Ogilvie A, et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods. 1999;223:77–92.
   PubMed Web of Science ®Google Scholar
• Katz U, Shoenfeld Y, Zandman-Goddard G. Update on intravenous immunoglobulins (IVIg) mechanisms of action and off- label use in autoimmune diseases. Curr Pharm Des. 2011;17:3166–3175.
   PubMed Web of Science ®Google Scholar
• Xiong Q, Feng J, Zhang Y, et al. Promotion of atherosclerosis in high cholesterol diet-fed rabbits by immunization with the P277 peptide. Immunol Lett. 2016;170:80–87.
   PubMed Web of Science ®Google Scholar
• Yong L, Yunxiao S, Qiyan X, et al. Immunization with P277 induces vascular leak syndrome in C57BL/6 mice via endothelial damage. Autoimmunity. 2010;43:654–663.
   PubMed Web of Science ®Google Scholar
• Foteinos G, Xu Q. Immune-mediated mechanisms of endothelial damage in atherosclerosis. Autoimmunity. 2009;42:627–633.
   PubMed Web of Science ®Google Scholar
• Poolsup N, Suksomboon N, Amin M. Efficacy and safety of oral antidiabetic drugs in comparison to insulin in treating gestational diabetes mellitus: a meta-analysis. .PLoS One. 2014;9:e109985.
   PubMed Web of Science ®Google Scholar
• Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet. 2001;358:221–229.
   PubMed Web of Science ®Google Scholar
• Harjutsalo V, Sjoberg L, Tuomilehto J. Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet. 2008;371:1777–1782.
   PubMed Web of Science ®Google Scholar
• Drexhage HA, Dik WA, Leenen PJM, et al. The immune pathogenesis of type 1 diabetes: not only thinking outside the cell but also outside the islet and out of the box. Diabetes. 2016;65:2130–2133.
   PubMed Web of Science ®Google Scholar
• Gao N, Yan C, Lee P, et al. Dendritic cell dysfunction and diabetic sensory neuropathy in the cornea. J Clin Invest. 2016;126:1998–2011.
   PubMed Web of Science ®Google Scholar
• Summers KL, Behme MT, Mahon JL, et al. Characterization of dendritic cells in humans with type 1 diabetes. Ann N Y Acad Sci. 2003;1005:226–229.
   PubMed Web of Science ®Google Scholar
• Thomas R. Dendritic cells as targets or therapeutics in rheumatic autoimmune disease. Curr Opin Rheumatol. 2014;26:211–218.
   PubMed Web of Science ®Google Scholar
• Ganguly D, Haak S, Sisirak V, et al. The role of dendritic cells in autoimmunity. Nat Rev Immunol. 2013;13:566–577.
   PubMed Web of Science ®Google Scholar
• Suwandi JS, Toes RE, Nikolic T, et al. Inducing tissue specific tolerance in autoimmune disease with tolerogenic dendritic cells. Clin Exp Rheumatol. 2015;33:S97–S103.
   PubMed Web of Science ®Google Scholar
• Steinman RM. Decisions about dendritic cells: past, present, and future. Annu Rev Immunol. 2012;30:1–22.
   PubMed Web of Science ®Google Scholar
• Benson RA, Patakas A, Conigliaro P, et al. Identifying the cells breaching self-tolerance in autoimmunity. J Immunol. 2010;184:6378–6385.
   PubMed Web of Science ®Google Scholar
• Sun SC, Chang JH, Jin J. Regulation of nuclear factor-κB in autoimmunity. Trends Immunol. 2013;34:282–289.
   PubMed Web of Science ®Google Scholar
• Mayer C, Berod L, Sparwasser T. Layers of dendritic cell-mediated T cell tolerance, their regulation and the prevention of autoimmunity. Front Immunol. 2012;3:183.
   PubMed Web of Science ®Google Scholar
• Kleijwegt FS, Laban S, Duinkerken G, et al. Transfer of regulatory properties from tolerogenic to proinflammatory dendritic cells via induced autoreactive regulatory T cells. J Immunol. 2011;187:6357–6364.
   PubMed Web of Science ®Google Scholar
• Huurman VAL, Der Meide PEV, Duinkerken G, et al. Immunological efficacy of heat shock protein 60 peptide DiaPep277 therapy in clinical type I diabetes. Clin Exp Immunol. 2008;152:488–497.
   PubMed Web of Science ®Google Scholar